MARKET RESEARCH STORE

The Chinese Pharmaceutical Market to

2024 - Commercial & Strategic
developments in the Chinese
Pharmaceutical Market to 2024
From 2008 to 2013, Chinas OTC drugs market reported an average growth of
15% with the market reaching $20.6bn in 2013 up from to $11bn in 2008 but
what will it be this year? Next year? And in 5 years time?

The Chinese Pharmaceutical Market to 2024 Commercial & Strategic developments in the
Chinese Pharmaceutical Market to 2024
Commercial
&
Strategic
developments
Pharmaceutical Market to 2024

in

the

Chinese

Capture or increase your foothold in the Chinese market

TODAY
Establish partnerships to manufacture, distribute or develop
Chinese products

 Establish anti-counterfeiting systems today to increase market

size and revenue
From 2008 to 2013, Chinas OTC drugs market reported an average
growth of 15% with the market reaching $20.6bn in 2013 up from
to $11bn in 2008 but what will it be this year? Next year? and in 5
years time?
The OTC drugs market in China was characterised by a late start,
but fast growth, along with huge potential in comparison to that of
the mature OTC markets in many western countries. Your company
should be benefiting from this market access and this is only the
OTC market what has the growth been throughout the whole
Chinese pharma sector? This report will tell you.

Read Full Report with TOC:

http://www.marketresearchstore.com/report/the-chinesepharmaceutical-market-to-2024--commercial-856
Chinas pharmaceutical sales growth is based on economic growth in
the country: This has resulted in increased healthcare expenditure
internally, and increased manufacture and export. Increasing
urbanisation, disposable income, aging population, health
education, lifestyle diseases and government investments and
initiatives for healthcare infrastructure improvement have helped
the market growth considerably. Have you captured enough of the
Chinese market?
Annually, an average of $190 is spent for the treatment of diabetes,
per patient, in China. By 2030, in China, diabetes is expected to

cost Yuan 173.4bn ($28 bn) a year. China is expected to top the
worlds diabetes tables both in terms of sheer numbers and
population prevalence. This is true across a range of complaints and
products types your company must capture a segment of this
market TODAY.
Buy copy of Report:
http://www.marketresearchstore.com/checkout/reportId/8
56/reportType/0
Anti-Counterfeiting and anti-corruption How the Chinese market is
changing
Counterfeit drugs are successfully introduced in to the lengthy and
complicated delivery chain because of the highly fragmented nature

of the market. A lack of regular inspections by any recognised drug

enforcement / regulatory bodies, again due to the highly
fragmented nature of production, allows counterfeit / poor quality
drugs into the Chinese pharma market. Moreover, wide spread
corruption also helps the distribution of counterfeit drugs. What are
the Chinese regulators, and the global manufacturers doing to
change this? Find out in this unique report.
Increased inward investment from multiple Big Pharma companies
has driven investment in R&D centres as well as opportunities for
Chinese graduates. Many graduates are staying in China; those that
have left now have jobs to return to. Are you producing enough of
your products in China? Increase your profitability through this
channel.

Domestically, increased levels of health insurance, increased health

education, rising numbers of hospitals and increased per capita
income have all driven the Chinese pharmaceutical market.
Increase in healthcare expenditure per capita, from $157in 2008 to
$278 in 2011
Increasing income and population. The middle class population
reached 400m in 2010 and is expected to reach 500m by 2015
In 2012, the central government alone invested CNY 24.3bn
($3.9bn) to improve health service infrastructure.
Key life style changes, which have accelerated the diseases such as
obesity, diabetes, cardiovascular, chronic respiratory diseases

The over 65 population has increased to 9.1% of the total

population in China in 2011 from 8.3% in 2008
This report also breaks down the market in terms of current drugs
and products that occupy the Chinese market at present; examining
the key prescription and OTC drugs that drive the Chinese market.
In addition to this crucial information this report offers analysis and
opinion on current R&D in the country alongside in depth analysis of
the evolving, global inward investment.
Discover exactly what the industry leaders are doing TODAY Industry information sourced exclusively for this report. This
information is not available anywhere else

Utilising primary and secondary research sources, GMR Data have

interviewed leading specialists within big pharma, R&D,
wholesalers, distributors, marketers and key organisations
specializing in access to the Chinese market, as well as Chinese
pharmaceutical companies accessing the global market. From these
interviews we have selected original, exclusive, transcribed
interviews with leading specialists in their field This information is
not available anywhere else.
This GMR Data report is the single tool to equip you with the latest
trends in all pharma sectors and why all stakeholders demand
development of the Chinese pharmaceutical market. This report will
arm you with all you and your company require to develop, price,
launch and market a product in China, or compete with a Chinese
product launched in your market.

With over 160 pages, and over 140+ charts, tables, figures and
graphs, this dedicated specialist report will ensure you remain
equipped and fully informed, to succeed in this competitive market.
Table of Content
1. Executive Summary
1.1. Chinese Pharmaceutical Market Review
1.2. Chapter Breakdown
1.3. Research and Analysis Methods
2. Drivers & Restraints of the Chinese Pharmaceutical Market
2.1 An Ageing Population will drive pharmaceutical market growth
in China

2.2 Increase in Chinese urbanisation

2.3 Increase in Healthcare expenditure will increase drug demand in
China
2.4 Government policies and changing environment for MNCs in
China
2.5 Increased demand for improved drug quality
2.6 Healthcare Reform in China
2.7 Path to privatization of Chinese healthcare
2.8 Consolidation of the pharmaceutical distribution industry in
China
2.9 Increase in lifestyle related diseases
2.10 Biotechnology Market: The Strategic Industry for China
2.11 Focus on GMP leads to Quality and Compliance reforms
2.12 Government led initiatives to attract foreign players
2.13 Talent Pool Availability

2.14 Increased Outsourcing of Drug Discovery boosting the Chinese

CRO Market
2.15 Regulatory Environment
2.15.1 Drug filing
2.15.2 Advertisements
2.15.3 Drugs Pricing & Reimbursement
2.16 Traditional Chinese Medicine
3. China Pharmaceutical Market Forecast
3.1 Chinese Pharmaceutical Market; Pharmaceutical Sales (OTC and
Prescription market)
3.1.1 Chinese pharmaceutical sales market Forecast 2008-2024
3.1.2 China Pharmaceutical Sales Market by Generic and Patented
Drug Sales
3.1.3 Generic Drugs Market in China

3.2 The Chinese Patented Drugs Market

3.3 China Pharmaceutical Sales Market by Prescription and OTC
Drug Sales
3.3.1 Prescription Drug Market in China
3.3.2 Over-the-Counter Drugs Market in China
4. The Chinese Medical Device Market
4.1 Overview of the Medical Device Market in China
4.2 China Medical Devices Market: Diagnostic Imaging Segment
4.3 China Medical Devices Market: Patient Aids Segment
4.4 China Medical Devices Market: Consumables Segment
4.5 The China Medical Devices Market: Dental Segment
4.6 China Medical Devices Market: Orthopaedic Segment
4.7 Challenges & Opportunities in the Medical devices market
4.7.1 Opportunities

4.7.2 Challenges
4.8 China Medical Devices Market: Players Landscape
4.8.1 Multinational Corporations in the Chinese Medical devices
market
4.8.1.1 General Electric Healthcare
4.8.1.1 Medtronic, Inc.
4.8.1.2 Zimmer - Zimmer Holdings, Inc.
4.8.1.3 Stryker Corporation
4.8.1.4 Siemens Healthcare
4.8.1.5 Johnson & Johnson
4.8.1.6 Philips Healthcare (Suzhou) Co., Ltd
4.9 Key Domestic companies in the Chinese Medical devices market
4.9.1 Weigao group
4.9.2 Mindray Medical International Limited
4.9.3 MicroPort Scientific Corporation

4.9.4 Biosensors International Group, Ltd

5. The Chinese API Market
5.1 API Overview
5.1.1 Global API Market
5.1.1.1 APAC API Market
5.1.1.2 The Chinese API Market
5.2 Major Growth Drivers for the Chinese API Market
5.3 Key Challenges
5.4 China API Market: Players Landscape
5.4.1 Major Chinese API Manufacturers
5.4.1.1 Zhejiang Hisun Pharmaceutical Co. Ltd
5.4.1.2 Jiangsu Hengrui Medicine Co., Ltd
5.4.1.3 CSPC Pharmaceutical Group Limited

5.4.1.4 Shandong Xinhua Pharmaceutical Company Limited

5.4.1.5 Shanghai Pharma Holding Company Limited
5.4.1.6 North China Pharmaceutical Group Corp.
6 Key Chinese Therapeutic Markets
6.1 Cardiovascular Diseases
6.1.1 Chinese Cardiovascular Disease treatments market forecast
2014-2024
6.2 Infectious Diseases
6.2.1 Chinese Infectious Disease treatments market forecast 20142024
6.3 Oncology
6.3.1 Chinese Oncology treatments market forecast 2014-2024

6.4 Nervous System

6.4.1 The Chinese Nervous System market forecast 2014-2024
6.5 Alimentary Tract & Metabolism
6.5.1 The Chinese Alimentary Tract & Metabolism treatments
market forecast 2014-2024
7. Major Players
7.1 Pfizer
7.2. Bayer
7.3. Sanofi-Aventis
7.4. AstraZeneca
7.5. Roche
7.6. Merck and Co.

7.7. Novartis
7.8. GSK
7.9. Novo Nordisk (Novo Nordisk (China) Pharmaceutical Co., Ltd.)
8. Expert Opinion
8.1 Dr Cezary Statuch Vice President Bristol-Myers Squibb, China
8.2 Dr Eugene Buff Primary Care Innovation Consulting & UsTech
Discovery LLC
Read Full Report/Request for Sample:
http://www.marketresearchstore.com/report/the-chinesepharmaceutical-market-to-2024--commercial-856

About Us
MarketResearchStore.com is a single destination for all the
industry, company and country reports. We feature large
repository of latest industry reports, leading and niche company
profiles, and market statistics released by reputed private
publishers and public organizations.
Market Research Store
Address: Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442, USA
Tel: +1-386-310-3803

Tel: +1-855-465-4651 (US/CAN TOLL FREE)

Email: sales@marketresearchstore.com

Web : http://www.marketresearchstore.com